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Quantitative proteomic approach for identification of differentially expressed
proteins after Primary Percutaneous Coronary Intervention in ST-segment
elevation Myocardial Infarction
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Background: Acute coronary syndrome with ST elevation is one of the most important
cardiovascular diseases affecting developed countries worldwide. The revascularization
of occluded arteries with primary percutaneous coronary intervention (PCI) has been
shown to reduce infarct size, reinfarction rates, the presence of new episodes of
ischemia, and to increase patient survival. Blood plasma, the most important biological
sample in clinical practice due to the information on the physiological status of the
body it contains, was used for the proteomic study of patients undergoing PCI.
Methods: Our aim was to search differentially expressed proteins before and after
recovery of flow in plasma of patients with ST-segment elevation myocardial infarction
(STEMI) using two-dimensional fluorescence difference gel electrophoresis (2D-
DIGE) and MALDI-TOF/TOF mass spectrometry. Pre and post- primary PCI plasma
samples of 18 patients with STEMI were recruited from the Cardiology Service of
Hospital Virgen de la Salud. All plasma samples were depleted from major proteins
(MARS Hu-14, Agilent Technologies) and then analyzed by 2D-DIGE and MALDI-
TOF/TOF.
Results: We found 37 differentially expressed proteins spot in depleted plasma. Results
of this experiment are currently being validated by immunoblotting and Multiple
Reaction Monitoring (MRM).
Conclusion: We expect 2D-DIGE proteomic analysis allow us to find differential
expressed proteins that could be used as potential biomarkers for monitoring the
recovery of flow in STEMI patients with important potential implication in clinical
recommendation for primary PCI.
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Copeptin: An Ultra Early Prognostic Marker for Acute Myocardial Infarction
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Background: Precise risk stratification is essential for the selection of early invasive
and pharmacoinvasive treatment in acute myocardial infarction (AMI) patients. An
emerging biomarker - copeptin, which is the C-terminal part of vasopressin
prohormone, appears to be a good acute event predictor of AMI patients.
Methods: In this single-centre observational study, we studied 54 consecutive post–
AMI patients. Endpoints were captured in day 7 after AMI. Copeptin level was
analyzed retrospectively from archive by commercial kits after calibration. The AMI
patients were grouped according to the administrative level of copeptin – high copeptin
and low copeptin group, in which their baseline characteristics and clinical endpoints
were compared. The primary endpoint is the composite cardiovascular endpoints of
death, cardiogenic shock and refractory ventricular tachycardia/ventricular fibrillation
(VT/VF). Other endpoints of interests are incidence of non–refractory VT/VF between
the two groups
Results: Baseline characteristics between the high and low copeptin group showed no
statistically significant difference (p>0.1). The primary composite cardiovascular
endpoint of death, cardiogenic shock and refractory VT/VF was observed in 75%
patients in high copeptin group and was observed in 19.6% patients in low copeptin
level group (p=0.0038). In individual outcome analysis, cardiogenic shock is
significantly higher in high copeptin group (p=0.0038). Death and refractory VT/VF
increased in high copeptin group but are statistically insignificant (p>0.1). Secondary
endpoint showed non refractory VT/VF was more often observed in high copeptin
group (p=0.0118)
Conclusion: Copeptin may be a good biomarker for risk stratification in AMI
management. It has strong association with cardiogenic shock and may be able to
predict cardiogenic shock in acute phase of post AMI patients. High copeptin level is
associated with non refractory VT/VF. Early invasive or pharmacoinvasive treatment
strategy may be indicated in patients with high copeptin level but further confirmation
with a larger, multicenter study is essential.
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Prognosis after Primary Percutaneous Coronary Intervention for ST-elevation
Myocardial Infarction is Predicted by Extent and Complexity of Coronary
Artery Disease as Assessed by the SYNTAX Score
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Background: Factors known to alter prognosis after PPCI for STEMI include age,
diabetes and ventricular function. Debate continues over optimal revascularisation
strategy (immediate, staged or culprit-only), but relatively little is known about the
impact of extent and complexity of coronary disease on prognosis after PPCI. The
SYNTAX score has been validated in multivessel/left main stem intervention; to date
no published studies have assessed its utility in PPCI.
Methods: Consecutive patients attending a single center undergoing PPCI between
Sep 2008 and Jun 2010 (n=695) were included. SYNTAX scoring was performed by
an operator blinded to patient details/outcomes and validated by comparative analysis
by 2 other operators. Patients were subsequently divided into terciles as in the
SYNTAX trial. Patient data and outcomes were obtained by interrogation of local and
national databases.
Results: 674/695 patients (mean age 64.1±12.5 years, 78.4% male) were included in
the analysis (21 excluded; prior CABG, images unavailable). Allocation of SYNTAX
tercile was reproducible between observers (Kappa = 0.75). Overall median SYNTAX
score was 19, with scores of 14(L n=437), 26(IM n=170) and 36(H n=67) in each
tercile. Age (p=<0.001), diabetes (p=0.004), elevated creatinine (p=<0.001) and prior
MI (p=0.004) were associated with increasing tercile. Overall 1-year mortality was
7.9%; 1-year absolute survival by increasing SYNTAX tercile was 94.9%, vs. 90.5%,
vs. 85.7%(p=0.002). 1-year freedom from mortality and unplanned revascularization
(MACE) was 92.2% vs. 86.9% vs. 79.4%(p=<0.001). Only SYNTAX score (p=0.04)
and cardiogenic shock (p=<0.001) were independent predictors of MACE.
Conclusion: The SYNTAX score, when applied to an unselected population
undergoing PPCI for STEMI, provides useful prognostic information regarding 1-year
survival from death and unplanned revascularisation. These findings may provide
supporting evidence towards complete revascularisation of non-culprit coronary artery
disease following PPCI.
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Background: The impact of door-to-balloon (DTB) time on long-term clinical
outcome in patients with ST-segment elevation myocardial infarction (STEMI)
undergoing primary percutaneous coronary intervention (PCI) has not been adequately
established in daily clinical practice in Japan.
Methods: We evaluated the relation between the DTB time and 3-year clinical outcome
in 3391 STEMI patients with primary PCI within 24 hours of symptom onset.
Results: In the entire study population, there was no significant difference in the
incidence of all-cause death (12.4% versus 14.4%; p=0.21) or in a composite of
death/CHF (16.7% versus 18.4%; p=0.54) between the two groups of patients with
short DTB time (DTB time ≤ 90 minutes) and long DTB time (DTB time > 90
minutes). In patients presenting within 2 hours of symptom onset, a short DTB time
compared with a long DTB time was associated with a lower incidence of all-cause
death (9.5% versus 14.6%; p=0.02) and a composite of death/CHF (11.9% versus
18.1%; p=0.01), but not in patients presenting later (14.3% versus 14.1%; p=0.87,
19.7% versus 18.7%; p=0.44, respectively). After adjusting for confounders, short DTB
time was independently associated with lower risk for a composite of death/CHF in
patients with early presentation (adjusted HR: 0.58, 95%C.I: 0.38-0.87, p=0.009), but
not in patients with delayed presentation (adjusted HR: 1.57, 95%C.I: 1.12-2.18,
p=0.008). There was a significant interaction between DTB time and the time to
presentation (interaction p=0.01).
Conclusion: In patients with STEMI undergoing primary PCI in daily clinical practice
in Japan, the benefit of short DTB time on 3-year clinical outcome was limited to
patients with early presentation. Efforts to minimize the patient-related delay such as
social activities to raise awareness for patients’ early visit to hospital should be
recommended to improve clinical outcome of STEMI patients.
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Background: Drug eluting stents (DES) use in patients with acute myocardial
infarction (AMI) is still under debate. The purpose of this study was to assess the
frequency and predictors of DES use in patients with AMI.
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